# ImmunOs Therapeutics

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/immunos-therapeutics

- Industry: Biotechnology
- Headquarters: Zurich, Switzerland
- Website: www.immunostherapeutics.com
- Total disclosed funding: $98M
- Latest round: Series C (Sep 17, 2024)
- Investors on record: 14

## About

Based in Zurich, ImmunOs Therapeutics AG specializes in developing biologic therapeutics that harness a unique HLA-based technology platform to treat severe autoimmune disorders and cancer.ImmunOs Therapeutics AG, founded in 2014 in Zurich, Switzerland, focuses on the development of therapeutics aimed at enhancing immune responses. The company has successfully raised funding totaling USD 11.00 mn in its most recent SERIES C round on September 17, 2024, involving significant investors such as BioMed Partners and Pfizer Venture Investments. Osiris Belaunzaran is the founder, with Sean Smith serving as the CEO.ImmunOs Therapeutics specializes in the development of biologic therapeutics that leverage a unique HLA-based technology platform. Their core product, IOS-1002, aims to hyper-activate the immune system in patients suffering from severe autoimmune disorders and various forms of cancer, designed for healthcare providers, oncologists, and specialists in immunotherapy in North America and Europe.ImmunOs Therapeutics generates revenue primarily through partnerships with pharmaceutical companies and clinical trial collaborations, notably with Merck, emphasizing B2B transactions. Their revenue streams derive from milestone payments and licensing agreements associated with IOS-1002 and partnerships for developing their innovative pipeline of immunotherapies.In September 2024, ImmunOs Therapeutics AG raised USD 11 mn in SERIES C funding, co-led by Gimv, Pfizer Venture Investments, Mission BioCapital, and BioMed Partners, with participation from Double Point Ventures. The funding will support the acceleration of clinical trials for their lead program, IOS-1002, as they aim to expand their presence in key markets.

## Funding rounds

- Series C, Sep 17, 2024, $11M — Gimv, BioMed Partners, Pfizer Venture Investments, Mission Biocapital, Double Point Ventures
- Series B, Jun 7, 2022, $72M — Schroders Capital, Lightspeed Venture Partners, Gimv, BioMed Partners, Pfizer Venture Investments, PEAK6 Investments, Redalpine, GL Capital Group, Mission Biocapital, Samsara BioCapital, Fiscus Financial
- Series A, Dec 10, 2019, $15M — Schroders Capital, BioMed Partners, Pfizer Venture Investments, Redalpine, Bernina BioInvest AG, Wille Finance

## Investors

- Schroders Capital (https://capitalatlas.ai/funds/schroders-capital) — Series A, Series B
- BioMed Partners (https://capitalatlas.ai/funds/biomed-partners) — Series A, Series B, Series C
- Pfizer Venture Investments (https://capitalatlas.ai/funds/pfizer-venture-investments) — Series A, Series B, Series C
- Redalpine (https://capitalatlas.ai/funds/redalpine) — Series A, Series B
- Bernina BioInvest AG — Series A
- Wille Finance — Series A
- Lightspeed Venture Partners (https://capitalatlas.ai/funds/lightspeed-venture-partners) — Series B
- Gimv (https://capitalatlas.ai/funds/gimv) — Series B, Series C
- PEAK6 Investments (https://capitalatlas.ai/funds/peak6-investments) — Series B
- GL Capital Group (https://capitalatlas.ai/funds/gl-capital-group) — Series B
- Mission Biocapital (https://capitalatlas.ai/funds/mission-biocapital) — Series B, Series C
- Samsara BioCapital (https://capitalatlas.ai/funds/samsara-biocapital) — Series B
- Fiscus Financial — Series B
- Double Point Ventures (https://capitalatlas.ai/funds/double-point-ventures) — Series C